(NASDAQ: ALEC) Alector's forecast annual revenue growth rate of 13.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Alector's revenue in 2026 is $18,417,000.On average, 10 Wall Street analysts forecast ALEC's revenue for 2026 to be $777,287,334, with the lowest ALEC revenue forecast at $277,007,842, and the highest ALEC revenue forecast at $2,331,528,927. On average, 10 Wall Street analysts forecast ALEC's revenue for 2027 to be $5,064,413,905, with the lowest ALEC revenue forecast at $455,203,267, and the highest ALEC revenue forecast at $17,452,049,145.
In 2028, ALEC is forecast to generate $1,382,929,729 in revenue, with the lowest revenue forecast at $455,203,267 and the highest revenue forecast at $3,200,301,015.